Figure 4. Factors associated with the risk of low‐density lipoprotein (LDL)–lowering therapy interruption.

In this figure, patients aged ≥65 years living in the South vs Northeast census region and patients not taking a statin or ezetimibe at the time of proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) initiation were more likely to have an interruption in all LDL‐lowering therapies in the year following initiation. CAD indicates coronary artery disease; CVD, cardiovascular disease; PAD, peripheral artery disease; and TIA, transient ischemic attack.